Vimarsana
Biggest News Aggregation in the World

Page 7 - Accurium News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Accurium. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Accurium Today - Breaking & Trending Today

Curium to become major player in the supply on non carrier - Vimarsana News

Curium to become major player in the supply on non carrier

London, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Today Curium has announced a technology license agreement granting access to ECZACIBAŞI MONROL NÜKLEER ÜRÜNLER...

Curium to become major player in the supply on non carrier added Lu-177 - Vimarsana News

Curium to become major player in the supply on non carrier added Lu-177

London, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Today Curium has announced a technology license agreement granting access to ECZACIBASI MONROL NÜKLEER ÜRÜNLER SANAYI VE TICARET A.S non carrier added Lutetium

Curium is pleased to announce that Sakir Mutevelic MD, MSc - Vimarsana News

Curium is pleased to announce that Sakir Mutevelic MD, MSc

London and Paris, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Curium welcomes Sakir Mutevelic MD, MSc. As Chief Medical Officer, Sakir leads Curium’s global...

Curium is pleased to announce that Sakir Mutevelic MD, MSc has joined as global Chief Medical Officer - Vimarsana News

Curium is pleased to announce that Sakir Mutevelic MD, MSc has joined as global Chief Medical Officer

London and Paris, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Curium welcomes Sakir Mutevelic MD, MSc. As Chief Medical Officer, Sakir leads Curium's global medical strategy and clinical development for diagnostic

Investegate |Curium Announcements | Curium: Curium Initiates ECLIPSE, a Phase 3 Clinical Trial For Its Investigational Lu 177 PSMA I&T - Vimarsana News

Investegate |Curium Announcements | Curium: Curium Initiates ECLIPSE, a Phase 3 Clinical Trial For Its Investigational Lu 177 PSMA I&T

Investegate announcements from Curium, Curium Initiates ECLIPSE, a Phase 3 Clinical Trial For Its Investigational Lu 177 PSMA I&T